Hello, Welcome to Shine Consultant !
Summit & Event Shine Speaker Bureau Shine Advisor Shine Event Service
  • Summit & Event :
    With field research of markets and industries which is analyzed from a global strategic perspective by our professional teams, as well as hot topics which interest leadership and management, Shine Consultant provides you with one-stop platform of dialogue, practice -sharing and social network!
  • Shine Speaker Bureau:
    Committed to provide keynote speakers, executive learning masterclasses and boardroom advisory for global enterprises and institutions, each service provides a deeper and more interactive experience, especially for small, selected audiences and key individuals. We have the resources of the most influential business leaders and experts, who are the most outstanding representatives in their fields. Our team consists of experienced speech and event managers, and we focus on building long-term and in-depth partnerships.
  • Shine Advisor:
    As world-class insight network, we connects clients-decision makers with vetted subject matter experts-advisors. Our clients leverage the insights and perspectives shared by our advisors to stay informed and make better business decisions.We have over 600,000 Shine Advisors in 20 industries, which continues to grow every day.
  • Shine Event Service:
    Committed to be the world's most professional provider of industrial Summit & Event. We provide one-stop professional services, including investigating and planning, on-demand inviting, marketing and promoting, operating, project management, live& digital conference, each service is performed by an experienced professional team matched with long-term industrial resources. We focus on establishing long-term and in-depth partnerships.
Conference Sponsor
394
2022 - 08 - 19
点击次数:
Parasoft成立于1987年,目前在上海、北京、成都、深圳、郑州等地设有研发中心和办事处。Parasoft是全球公认的软件质量、服务虚拟化及软件生命周期管理解决方案,并且还是AEP(软件自动化错误预防)理论的创始者,与此同时,Parasoft产品横跨单元测试、静态分析、动态分析、功能测试、压力测试、信息安全测试、通信协议仿真、应用环境虚拟化等,拥有超过30项软件质量相关专利以及40余项全球各类顶级奖项。
395
2020 - 03 - 11
点击次数:
SOTIO is an international biotechnology company leading the efforts of its strategic investor PPF Group to build a diverse pharma company specializing in oncology. SOTIO pursues its goal through in-house research and clinical development, collaboration with external partners, in-licensing deals, investments and acquisitions. The company is developing new therapies focusing on the treatment of cancer and autoimmune diseases. The most advanced project in the SOTIO development portfolio is based on its proprietary DCVAC platform – an active cellular immunotherapy (ACI) on the basis of dendritic cells. SOTIO is testing safety and efficacy of its DCVAC products in multiple Phase I to Phase III clinical trials in oncology indications. SOTIO has a geographic presence in Europe, the United States, China and Russia, enabling a global approach to clinical development. The GMP-certified cell therapy manufacturing facility in Prague, one of the largest of its kind in Europe, can manufacture and supply cellular immunotherapy treatment for clinical development in both Europe and the United States. In Beijing, SOTIO manufactures its products in its GMP-compliant cell therapy manufacturing facility built in 2014 for joint research projects and clinical trials conducted by leading hospitals in China.
396
2020 - 03 - 04
点击次数:
Nucleus Network is Australia’s largest and only global multi-site dedicated phase I clinical research organisation with phase I facilities located in Melbourne (80 beds), Brisbane (62 beds) and  Minnesota (52 beds).  The phase I units in Australia are strategically co-located within the Alfred Hospital in Melbourne (approx. 800 bed tertiary teaching hospital) and within the Royal Brisbane and Women’s Hospital (approx. 900 bed tertiary teaching hospital) in Brisbane. This combination also provides Nucleus Network with access to a combined population of 7.5 million people within Australia alone. Nucleus Network have extensive experience in the conduct of early phase study designs in healthy volunteers and patient populations eg. FIH SAD and MAD, drug interaction, food effect, bioequivalence, crossover, TQTc, ethnopharmacology, etc. Established in 2004, Nucleus Network has conducted over 750 phase I clinical trials, with 90% of clients being overseas (primarily the USA) pharmaceutical and biotech companies. Approximately 70 phase I studies are conducted annually per year at Nucleus with about 30 of these being true first-in-human studies. Nucleus has extensive experience with both biologics and small molecule products across most therapeutic areas.